Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Shorts Decreased by 0.41% After Short Covering

September 16, 2018 - By Benjamin Allen

The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) registered a decrease of 0.41% in short interest. EGRX’s total short interest was 2.58M shares in September as published by FINRA. Its down 0.41% from 2.59M shares, reported previously. With 215,900 shares average volume, it will take short sellers 12 days to cover their EGRX’s short positions. The short interest to Eagle Pharmaceuticals Inc’s float is 25.47%.

The stock decreased 0.09% or $0.06 during the last trading session, reaching $66.66. About 161,924 shares traded. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has risen 11.00% since September 16, 2017 and is uptrending. It has underperformed by 4.62% the S&P500.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company has market cap of $1.00 billion. The firm offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It has a 34.79 P/E ratio. The Company’s product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Ratings Coverage

Among 2 analysts covering Eagle Pharmaceuticals (NASDAQ:EGRX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Eagle Pharmaceuticals has $81 highest and $4000 lowest target. $71.50’s average target is 7.26% above currents $66.66 stock price. Eagle Pharmaceuticals had 5 analyst reports since March 21, 2018 according to SRatingsIntel. The company was maintained on Monday, May 7 by Mizuho. The firm has “Hold” rating by Mizuho given on Monday, June 11. The rating was maintained by Mizuho on Wednesday, March 21 with “Sell”. The firm has “Sell” rating given on Thursday, May 17 by Mizuho.

More news for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) were recently published by: Seekingalpha.com, which released: “Eagle Pharmaceuticals announces new patent issued for BENDEKA” on August 22, 2018. Nasdaq.com‘s article titled: “Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals …” and published on August 28, 2018 is yet another important article.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.